Marine-derived drugs in neurology

Current Opinion in Investigational Drugs

Volumn 8, Issue 7, 2007, Pages 525-530

  Martinez, A ^a  

^a NeuroPharma   (Spain)

Author keywords

Alzheimer's disease; Conotoxin; GTS 21; Neuropathic pain; Schizophrenia; Ziconotide

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ACV 1; AM 336; CALCIUM CHANNEL BLOCKING AGENT; CGX 1160; CONANTOKIN G; OMEGA 3 FATTY ACID; OMEGA CONOTOXIN; OMEGA CONOTOXIN MVIIA; PEPTIDE DERIVATIVE; SNX 239; UNCLASSIFIED DRUG; XEN 2174;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN ISCHEMIA; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONUS SNAIL; DRUG DOSE ESCALATION; DRUG ISOLATION; DRUG TARGETING; DRUG TOLERANCE; EPILEPSY; HUMAN; INTRACTABLE PAIN; MARINE SPECIES; MOLLUSC; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PHANTOM PAIN; POSTHERPETIC NEURALGIA; REVIEW; SINGLE DRUG DOSE;

ANIMALS; BIOLOGICAL FACTORS; CONUS SNAIL; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NERVOUS SYSTEM DISEASES; NEUROLOGY; OMEGA-CONOTOXINS; SEAWATER;

EID: 34347328113     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Newman DJ, Cragg GM, Snader KM: Natural products as sources of new drugs over the period 1981-2002. J Nat Prod (2003) 66(7):1022-1037.
2. Kingston DG, Newman DJ: Natural products as drug leads: An old process or the new hope for drug discovery? IDrugs (2005) 8(12):990-992.
3. Blunt JW, Copp BR, Munro MH, Northcote PT, Prinsep MR: Marine natural products. Nat Prod Rep (2006) 23(1):26-78.
4. Newman DJ, Cragg GM: Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod (2004) 67(8):1216-1238.
5. Newman DJ, Cragg GM: Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr Med Chem (2004) 11(13):1693-1713. •• A comprehensive review covering the development of marine drugs.
6. Alonso D, Castro A, Martinez A: Marine compounds for the therapeutic treatment of neurological disorders. Expert Opin Ther Pat (2005) 15(10):1377-1386. • The first specific review, focused mainly on patents, to describe marine compounds as potential therapies in neurology.
7. Terlau H, Olivera BM: Conus venoms: A rich source of novel ion channel-targeted peptides. Physiol Rev (2004) 84(1):41-68.
8. Livett BG, Gayler KR, Khalil Z: Drugs from the sea: Conopeptides as potential therapeutics. Curr Med Chem (2004) 11(13):1715-1723.
9. Sharp D: Novel pain relief via marine snails. Lancet (2005) 366(9484):439-440.
10. Schroeder CI, Doering CJ, Zamponi GW, Lewis RJ: N-type calcium channel blockers: Novel therapeutics for the treatment of pain. Med Chem (2006) 2(5):535-543.
11. Elan Corp plc: Products and pipeline. Company Communication (2005): April 21.
12. AMRAD Corp Ltd: Drug development pipeline: AM-336 and neurological drug candidates. Company Communication (2005):February 07.
13. Dutertre S, Lewis RJ: Toxin insights into nicotinic acetylcholine receptors. Biochem Pharmacol (2006) 72(6):661-670.
14. Sandall DW, Satkunanathan N, Keays DA, Polidano MA, Liping X, Pham V, Down JG, Khalil Z, Livett BG, Gayler KR: A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry (2003) 42(22):6904-6911.
15. Livett BG, Sandall DW, Keays D, Down J, Gayler KR, Satkunanathan N, Khalil Z: Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor. Toxicon (2006) 48(7):810- 829.
16. Wang CZ, Chi CW: Conus peptides - a rich pharmaceutical treasure. Acta Biochim Biophys Sin (Shanghai) (2004) 36(11):713-723.
17. Xenome Limited: Xen2174 is effective in the treatment of neuropathic pain. Press Release (2003): July 15.
18. Layer RT, Wagstaff JD, White HS: Conantokins: Peptide antagonists of NMDA receptors. Curr Med Chem (2004) 11(23):3073-3084.
19. Castellino FJ, Prorok M: Conantokins: Inhibitors of ion flow through the N-methyl-D-aspartate receptor channels. Curr Drug Targets (2000) 1(3):219-235.
20. Craig AG, Norberg T, Griffin D, Hoeger C, Akhtar M, Schmidt K, Low W, Dykert J, Richelson E, Navarro V, Mazella J et al: Contulakin-G, an O-glycosylated invertebrate neurotensin. J Biol Chem (1999) 274(20):13752-13759.
21. Barton ME, White HS, Wilcox KS: The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on NMDA receptor-mediated EPSCs. Epilepsy Res (2004) 59(1):13-24.
22. Klotz U: Ziconotide - a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain - a short review. Int J Clin Pharmacol Ther (2006) 44(10):478-483.
23. Wallace MS: Ziconotide: A new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother (2006) 6(10):1423-1428.
24. Malmberg AB, Yaksh TL: Effect of continuous intrathecal infusion of ω-conopetides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate test in rats. Pain (1995) 60(1):83-90.
25. Kelety B: Ion channels in drug discovery & development - SRI's Fourth Annual Conference, Philadelphia, PA, USA. IDDB Meeting Report (2004): October 04-05.
26. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce DA, Mangieri EA, Luther RR, Mayo M et al: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. J Am Med Assoc, (2004) 291(1):63-70.
27. Zhao Q, Khansari P, Luther RR: Neuroprotection by selective blockade of N-type neuronal calcium channels: Evidence for a wide therapeutic window in focal cerebral ischemia. International Symposium on Pharmacology of Cerebral Ischemia, Amsterdam, the Netherlands (1998) 7: Abs 73.
28. 2+- channel blocker prevents CA1 injury 24h following severe forebrain ischemia and reduces infarction following focal ischemia. J Cereb Blood Flow Metab (1994) 14(6):903-910.
29. Elan Corp plc: Annual Report 2001: Elan. Annual Report (2002): July 09.
30. Lewis RJ, Nielsen KJ, Craik DJ, Loughnan ML, Adams DA, Sharpe IA, Luchian T, Adams DJ, Bond T, Thomas L, Jones A et al: Novel ω-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem (2000) 275(45):35335- 35344.
31. Scott DA, Wright CE, Angus JA: Actions of intrathecal ω-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol (2002) 451(3):279-286.
32. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ: The novel N-type calcium channel blocker, AM336, produces potent dosedependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain (2002) 96(1-2):119-127.
33. Adams DJ, Smith AB, Schroeder CI, Yasuda T, Lewis RJ: ω-Conotoxin CVID inhibits a pharmacologically distinct voltage-sensitive calcium channel associated with transmitter release from preganglionic nerve terminals. J Biol Chem (2003) 278(6):4057-4062.
34. Radbruch L, Elsner F: Emerging analgesics in cancer pain management. Exp Opin Emerging Drugs (2005) 10(1):151-171.
35. Clark RJ, Fischer H, Nevin ST, Adams DJ, Craik DJ: The synthesis, structural characterization, and receptor specificity of the α-conotoxin Vc1.1. J Biol Chem (2006) 281(32):23254-23263.
36. Satkunanathan N, Livett B, Gayler K, Sandall D, Down J, Khalil Z: α-Conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res (2005) 1059(2):149-158.
37. Metabolic Pharmaceuticals Ltd: Metabolic's neuropathic pain drug, ACV1, enters phase 2 clinical trials. Press Release (2006): September 28
38. Metabolic Pharmaceuticals Ltd: Metabolic's phase 1 clinical trial demonstrates safety and tolerability of pain drug. Press Release (2005): November 16.
39. Layer RT, McIntosh JM: Conotoxins: Therapeutic potential and application. Mar Drugs (2006) 4(3):119-142. •• A comprehensive review of the pharmaceutical development of conotoxins.
40. Nielsen CK, Lewis RJ, Alewood D, Drinkwater R, Palant E, Patterson M, Yaksh TL, McCumber D, Smith MT: Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain (2005) 118(1-2):112-124.
41. Xenome Ltd: Xenome's pain drug Xen2174 enters human clinical trials. Press Release (2004): July 20.
42. Xenome Ltd: Xenome launches multicentre clinical trial for severe cancer pain. Press Release (2005): November 15.
43. Cognetix Inc: FDA grants orphan drug designation to Cognetix' investigational CGX-1160 for the treatment of chronic intractable pain. Press Release (2005): August 30.
44. Cognetix Inc: Cognetix announces issuance of US patent on contulakin-G to treat pain; first clinical safety study completed with CGX-1160. Press Release (2002): December 05.
45. Westerlind U, Norberg T: Chemical synthesis of analogs of the glycopeptide contulakin-G, an analgetically active conopeptide from Conus geographus. Carbohydr Res (2006) 341(1):9-18.
46. Williams AJ, Dave JR, Phillips JB, Lin Y, McCabe RT, Tortella FC: Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: In vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies. J Pharmacol Exp Ther (2000) 294(1):378-386.
47. Williams AJ, Ling G, McCabe RT, Tortella FC: Intrathecal CGX-1007 is neuroprotective in a rat model of focal cerebral ischemia. Neuroreport (2002) 13(6):821-824.
48. Cognetix Inc: Cognetix completes phase I clinical trial of intractable epilepsy treatment. Press Release (2001): May 30.
49. McCauley JA: R2B subtype-selective NMDA receptor antagonists: 2001 - 2004. Exp Opin Ther Patents (2005) 15(4):389-407.
50. Barton ME, White HS: The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res (2004) 59(1):1-12.
51. Kem WR, Soti F: Amphiporus alkaloid multiplicity implies functional diversity: Initial studies on crustacean pyridyl receptors. Hydrobiologia (2001) 456(1-3):221-231.
52. Kem W, Soti F, Wildeboer K, LeFrancois S, MacDougall K, Wei DQ, Chou KC, Arias HR: The nemertine toxin anabaseine and its derivative DMXBA (GTS-21): Chemical and pharmacological properties. Mar Drugs (2006) 4(3):255-273.
53. NCT00419445: Safety and efficacy of GTS21 in adults with attention-deficit hyperactivity disorder. National Institutes of Heath, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct/show/NCT00419445
54. Athenagen Inc: Athenagen initiates phase II clinical trial in Alzheimer's disease. Press Release (2006): December 13.
55. 7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry (2006) 63(6):630-638. • The first report on the efficacy of GST-21 in humans.
56. Nozawa Y, Nanri M, Kasahara N: Ex vivo receptor occupation of GTS-21, a novel nicotinic receptor agonist, in rats. Jpn J Pharmacol (1996) 71(Suppl 1):176.
57. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR: Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res (1995) 674(2):252-259.
58. 7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: Studies with DMXBA (GTS-21). Behav Brain Res (2000) 113(1-2):169-181. •• A comprehensive review of the involvement of nicotinic receptors in AD, and the discovery and optimization of GST-21.
59. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, Burnett AL: Safety, pharmokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology (2003) 28(3):542-551.
60. 7 receptors. Mol Pharmacol (2004) 66(1):14-24.
61. Kem WR, Mahnir VM, Prokai L, Papke RL, Cao X, LeFrancois S, Wildeboer K, Prokai-Tatrai K, Porter-Papke J, Soti F: Hydroxy metabolites of the Alzheimer's drug candidate GTS-21: Their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol (2004) 65(1):56-67.
62. Wei DQ, Sirois S, Du QS, Arias HR, Chou KC: Theoretical studies of Alzheimer's disease drug candidate 3-[(2,4-dimethoxy)-benzylidene]-anabaseine (GTS-21) and its derivatives. Biochem Biophys Res Commun (2005) 338(2):1059-1064.
63. 7 Nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. Psychopharmacology (2004) 174(1):54-64.
64. 7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP in β-amyloid infused rats. Neuropharmacology (2006) 50(2):254-268.
65. Young G, Conquer J: ω-3 Fatty acids and neuropsychiatric disorders. Reprod Nutr Dev (2005) 45(1):1-28.
66. Saugstad LF: Are neurodegenerative disorder and psychotic manifestations avoidable brain dysfunctions with adequate dietary ω-3? Nutr Health (2006) 18(2):89-101.
67. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H: Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on β-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis (2006) 23(3):563-572.
68. Alonso D, Martinez A: Marine compounds as a new source for glycogen synthase kinase-3 inhibitors. In: Glycogen Synthase Kinase 3 (GSK-3) and its Inhibitors: Drug Discovery and Development. Martinez A, Castro A, Medina M (Eds), Wiley-VCH Verlag GmbH & Co KGaA, Berlin, Germany (2006):307-331. • New possibilities for marine compounds and their therapeutic application are described.
69. Martinez A, Castro A, Dorronsoro I, Alonso M: Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev (2002) 22(4):373-384.
70. Alonso M, Martinez A: GSK-3 inhibitors: Discoveries and developments. Curr Med Chem (2004) 11(6):755-763.
71. Meijer L, Thunnissen AMWH, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J et al: Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol (2001) 7(1):51-63.
72. Gompel M, Leost M, de Kier Joffe EB, Puricelli L, Franco LH, Palermo J, Meijer L: Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum. Bioorg Med Chem Lett (2004) 14(7):1703-1707.
73. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C et al: GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 10(12):1255-1266.
74. Rao KV, Donia MS, Peng J, Garcia-Palomero E, Alonso D, Martinez A, Medina M, Franzblau SG, Tekwani BL, Khan SI, Wahyuono S et al: Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. J Nat Prod (2006) 69(7):1034-1040.